Covalon Technologies Ltd.

Equities

COV

CA22282D3022

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 15:27:00 2024-06-05 EDT			5-day change	1st Jan Change
2.1 ^CAD	+0.48%		+22.09%	+98.11%

05-29	Transcript : Covalon Technologies Ltd., Q2 2024 Earnings Call, May 29, 2024
05-29	Covalon Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Covalon Announces Retirement of Myrna Francis from Board Member

September 24, 2021 at 08:12 am

Covalon Technologies Ltd. announced that Dr. Myrna Francis is retiring as a member of the Board of Directors of the Company, effective September 24, 2021, due to new professional commitments that will prevent her from continuing to commit time to Covalon.

Latest news about Covalon Technologies Ltd.

Transcript : Covalon Technologies Ltd., Q2 2024 Earnings Call, May 29, 2024	05-29
Covalon Technologies Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-29	CI
Transcript : Covalon Technologies Ltd. - Shareholder/Analyst Call	03-06
Covalon Technologies Ltd. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-28	CI
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows; Up 17.8%	01-26	MT
Covalon Technologies Reports Management Changes; Narrows Fiscal Q4 Loss, Revenue Grows	01-26	MT
Covalon Technologies Narrows Fiscal Q4 Loss, Revenue Grows	01-26	MT
Covalon Technologies Ltd. Announces Interim Chief Financial Officer Changes	01-26	CI
Covalon Technologies Ltd. Announces Appointment of Kim Crooks as Senior Vice President - Operations	01-26	CI
Covalon Technologies Brief: Reporting 2023-Q4 revenue of $6.9 million, an increase of 28%, and net loss from continuing operations of $2.9 million, an improvement of $1.2 million	01-26	MT
Covalon Technologies Ltd. Reports Earnings Results for the Full Year Ended September 30, 2023	01-26	CI
Covalon Technologies Ltd. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	01-26	CI
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	01-04	CI
Covalon Technologies Ltd. Announces Executive Changes	01-04	CI
Covalon Technologies Appoints MedTech Executive Brent Ashton as its New Chief Executive	01-04	MT
Covalon Technologies Brief: Appointing "Experienced" MedTech Executive Brent Ashton as New CEO	01-04	MT
Covalon Technologies Ltd. to Showcase Innovative Solutions at the Prestigious ANCC National Magnet Conference in Chicago	23-10-11	CI
Transcript : Covalon Technologies Ltd. - Special Call	23-09-27
Covalon Technologies Names Interim CEO; Begins Search for Permanent CEO	23-09-26	MT
Covalon Technologies Ltd. Announces Chief Executive Officer Changes	23-09-26	CI
Covalon Technologies Ltd. Appoints Joseph Cordiano as Independent Director	23-09-26	CI
Transcript : Covalon Technologies Ltd., Q3 2023 Earnings Call, Aug 16, 2023	23-08-16
Covalon Technologies Reports Total Q3 Revenue Increased 39% to $6.3 Million;	23-08-16	MT
Covalon Technologies Brief: Both net loss and net loss from continuing operations for the three months ended June 30, 2023 was $0.5 million or $0.02 per share	23-08-16	MT
Covalon Technologies Brief: Total revenue for the three months ended June 30, 2023 increased 39% to $6.3 million	23-08-16	MT

Chart Covalon Technologies Ltd.

Duration

Period

More charts

Company Profile

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalonâs name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
COVALON TECHNOLOGIES LTD.	+98.11%	37.79M
MODERNA, INC.	+55.70%	59.34B
LONZA GROUP AG	+42.66%	40.24B
IQVIA HOLDINGS INC.	-5.39%	39.88B
CELLTRION, INC.	-5.56%	28.55B
ICON PUBLIC LIMITED COMPANY	+16.46%	27.26B
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	19.23B
MEDPACE HOLDINGS, INC.	+33.03%	12.61B
UNITED THERAPEUTICS CORPORATION	+25.85%	12.28B
BIO-TECHNE CORPORATION	+2.72%	12.49B

Other Biotechnology & Medical Research